MIKKAEL SEKERES

Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology MIAMI, FL NPI 1497710941

General Payments — all program years on this page

$292,242.74

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 153
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $44,820.91 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $26,825.003
Travel and Lodging $15,454.427
Honoraria $2,220.001
Food and Beverage $321.497

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $23,281.066
Daiichi Sankyo Inc. $14,267.535
E.R. Squibb & Sons, L.L.C. $2,460.001
Karyopharm Therapeutics Inc. $2,445.001
Agios Pharmaceuticals, Inc. $2,224.232
Genmab U.S., Inc. $78.091
Celgene Corporation $65.002

By program year

Program yearAmountRecords
2018 $33,931.9233
2019 $33,793.0823
2020 $93,833.2842
2021 $50,949.1822
2022 $15,635.137
2023 $19,279.248
2024 $44,820.9118

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1089480565 Daiichi Sankyo Inc. $45.18 12/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1089480567 Daiichi Sankyo Inc. $13,066.00 05/20/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1089480569 Daiichi Sankyo Inc. $926.11 07/10/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1089480571 Daiichi Sankyo Inc. $162.63 07/10/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1089480573 Daiichi Sankyo Inc. $67.61 07/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101129094 Celgene Corporation $15.00 12/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101129096 Celgene Corporation $50.00 12/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101402125 E.R. Squibb & Sons, L.L.C. $2,460.00 02/20/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1104369651 AstraZeneca Pharmaceuticals LP $21,920.00 12/03/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1104408577 AstraZeneca Pharmaceuticals LP $83.54 03/04/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1104682243 AstraZeneca Pharmaceuticals LP $620.32 03/06/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1105459702 AstraZeneca Pharmaceuticals LP $374.18 03/04/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1105578622 AstraZeneca Pharmaceuticals LP $221.64 03/04/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1105602094 AstraZeneca Pharmaceuticals LP $61.38 03/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1126829846 Genmab U.S., Inc. $78.09 12/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1145533910 Karyopharm Therapeutics Inc. $2,445.00 04/23/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1149644631 Agios Pharmaceuticals, Inc. $2,220.00 01/03/2024 Honoraria Undisputed 01/23/2026 View at CMS
1149645418 Agios Pharmaceuticals, Inc. $4.23 12/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.